| 刘舜华,袁小凤,叶雪婷,张瑜良,赵莉,周坤元.阿立哌唑联合奥氮平治疗住院男性精神分裂症患者的效果及对代谢综合征的影响[J].四川精神卫生杂志,2024,37(3):226-231.Liu Shunhua,Yuan Xiaofeng,Ye Xueting,Zhang Yuliang,Zhao Li,Zhou Kunyuan,Efficacy of aripiprazole combined with olanzapine for hospitalized male patients with schizophrenia and its effect on metabolic syndrome[J].SICHUAN MENTAL HEALTH,2024,37(3):226-231 |
| 阿立哌唑联合奥氮平治疗住院男性精神分裂症患者的效果及对代谢综合征的影响 |
| Efficacy of aripiprazole combined with olanzapine for hospitalized male patients with schizophrenia and its effect on metabolic syndrome |
| 投稿时间：2023-09-16 |
| DOI：10.11886/scjsws20230916001 |
| 中文关键词: 精神分裂症 男性 阿立哌唑 奥氮平 代谢综合征 |
| 英文关键词:Schizophrenia Male Aripiprazole Olanzapine Metabolic syndrome |
| 基金项目:梅州市科技计划项目（项目名称：使用阿立哌唑片联合非典型抗精神病药干预精神分裂症代谢异常的研究，项目编号：2022B116） |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 背景 精神分裂症及抗精神病药物使用均可能导致患者发生代谢综合征（MS），增加心血管疾病的发生风险，不利于疾病预后。有效预防或降低精神分裂症患者伴发MS的风险至关重要。目的 探讨阿立哌唑联合奥氮平治疗男性精神分裂症的效果及其对患者MS的影响，以期为男性精神分裂症患者抗精神病药物的选择提供参考。方法 连续选取2023年2月—6月在梅州市第三人民医院住院治疗的、符合《国际疾病分类（第10版）》（ICD-10）精神分裂症诊断标准的80例男性患者。采用随机数表法分为研究组（阿立哌唑联合奥氮平口服）与对照组（奥氮平单药口服）各40例，两组均连续用药6周。治疗前，两组均接受阳性和阴性症状量表（PANSS）评定和MS相关指标［空腹血糖（FPG）、糖化血红蛋白（HbA1c）、体质量指数（BMI）、腰臀比（WHR）及血脂水平］、血清S100钙结合蛋白B（S100B）以及超敏C反应蛋白（hs-CRP）水平检测，于治疗第2、4、6周末再次行PANSS评定，于治疗第2周和第6周末进行临床疗效总评量表（CGI）评定，治疗第6周末再次进行MS相关指标、S100B以及hs-CRP水平检测及副反应量表（TESS）评定。结果 两组PANSS评分的组别效应、时间效应及组别与时间的交互效应均有统计学意义（F=18.092、634.780、2.917，P<0.05或0.01）。两组CGI评分的组别效应和时间效应均有统计学意义（F=20.492、99.190，P均<0.01）。治疗第6周末，研究组HbA1c和甘油三酯（TG）水平均低于对照组（t=-3.495、-3.293，P均<0.05）。治疗第6周末，研究组hs-CRP水平低于对照组（t=-3.916，P<0.05）。研究组TESS评分低于对照组（t=-4.684，P<0.01）。结论 与奥氮平单药治疗相比，阿立哌唑联合奥氮平可能更有助于改善男性精神分裂症患者的精神病性症状，且对MS相关指标的影响更小。 |
| 英文摘要: |
| Background Schizophrenia and the use of antipsychotic medications are identified to be the likely contributors to the development of metabolic syndrome （MS） and cardiovascular disease， and jeopardize the prognosis of schizophrenia. Therefore， effectively preventing or reducing the risk of developing MS in patients with schizophrenia is critical.Objective To explore the efficacy of aripiprazole combined with olanzapine for male schizophrenia patients and its effect on MS， so as to provide a certain reference for the selection of antipsychotic drugs for schizophrenia patients.Methods Male patients （n=80） who were hospitalized in The Third People's Hospital of Meizhou from February to June 2023 and fulfilling the International Classification of Diseases， tenth edition （ICD-10） diagnostic criteria for the schizophrenia were enrolled， and grouped using random number table method， each with 40 cases. Study group was treated with aripiprazole combined with olanzapine， while control group was given aripiprazole monotherapy. The treatment lasted for 6 continuous weeks in both groups. At the baseline， Positive and Negative Symptom Scale （PANSS） score， MS-related indices ［fasting plasma glucose （FPG）， hemoglobin A1c （HbA1c）， body mass index （BMI）， waist-to-hip ratio （WHR）， lipid profile］， S100 calcium-binding protein B （S100B） and high sensitivity C-reactive protein （hs-CRP） were recorded. Then the PANSS scores at the end of the 2nd， 4th and 6th week of treatment， the Clinical Global Impression （CGI） scores at the end of the 2nd and 6th week of treatment， as well as the MS-related indices， S100B， hs-CRP， Treatment Emergent Symptom Scale （TESS） score and Rating Scale for Extrapyramidal Side Effects （RSESE） score at the end of the 6th week of treatment were recorded in all participants.Results Analysis on PANSS score revealed a significant group effect， time effect and group×time interaction effect （F=18.092， 634.780， 2.917， P<0.05 or 0.01）. Analysis on CGI score revealed a significant group effect and time effect （F=20.492， 99.190， P<0.01）. At the end of the 6th week of treatment， study group detected lower serum concentrations of HbA1c and triglyceride （TG） compared with control group （t=-3.495， -3.293， P<0.05）. The post-treatment hs-CRP level was lower in study group than that in control group （t=-3.916， P<0.05）. Study group scored lower on TESS compared with control group （t=-4.684， P<0.01）.Conclusion Aripiprazole combined with olanzapine can effectively alleviate psychotic states in male schizophrenia patients， and the combination therapy yields less impact on MS-related indices than olanzapine monotherapy. ［Funded by Meizhou Science and Technology Plan Project （number， 2022B116）］ |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |